

~ Updates on HPMS Memos ~

<b>CMS Memo Title &amp; Release Date</b>	Medicare Advantage Prescription Drug System (MARx) May 2022 Payment – INFORMATION – Dated 04/22/2022
<b>Summary</b>	<p>CMS provided information about the May 2022 payment scheduled for April 29, 2022, and may require plan action for the following:</p> <ul style="list-style-type: none"> <li>• MARx used 2021 Part C and D Default Risk Factors for 2022 Payments</li> <li>• Sequestration Suspension</li> <li>• 2022 Frailty Score Update</li> <li>• Changes to MARx Plan Transaction Processing</li> </ul>
<b>Action - PACE</b>	Applicable to PACE. Refer to the memo for complete details and items that may be applicable to your plan.
<b>Action - MAPD</b>	Applicable to MAPD. Refer to the memo for complete details and items that may be applicable to your plan.
<b>CMS Memo Title &amp; Release Date</b>	UPDATES – 2022 Medicare Part D Patient Safety Reports – Dated 04/21/2022
<b>Summary</b>	The purpose of this memo is to announce the availability of the 2022 Patient Safety Reports on the Patient Safety Analysis Web Portal on April 29, 2022, updates to measure calculations, changes to measure specifications, new measures, and archiving of older reports. To access the Patient Safety Reports, you must be an authorized user of the Patient Safety Web Portal. The access authorization process is described later in this memo.
<b>Action - PACE</b>	Applicable to PACE. Refer to the memo for complete details and how to access the Patient Safety Analysis Web Portal and add/change user authorization access.
<b>Action - MAPD</b>	Applicable to MAPD. Refer to the memo for complete details and how to access the Patient Safety Analysis Web Portal and add/change user authorization access.
<b>CMS Email Title &amp; Release Date</b>	Total Beneficiary Cost Data for Contract Year 2023 Bid Preparation—CORRECTION – Dated 04/25/2022
<b>Summary</b>	Plan-specific Total Beneficiary Cost information that organizations must use to determine compliance with TBC standards is located in the following HPMS pathway: Quality and Performance > Performance Metrics > Reports > Costs > Part C Total Beneficiary Costs. Information in

	columns B and C under CY 2022 Total Beneficiary Cost has been corrected.
<b>Action - PACE</b>	Informational to PACE as PACE is waived of the out-of-pocket requirements.
<b>Action - MAPD</b>	Applicable to MAPD.
<b>CMS Memo Title &amp; Release Date</b>	Closing the Drug Data Processing System (DDPS) for benefit year 2015 – Dated 04/25/2022
<b>Summary</b>	CMS will close the DDPs to PDE data with dates of services (DOS) for benefit year 2015 which will take effect on July 1st, 2022. Any PDE data submitted with DOS for 2015 after June 30, 2022 will reject with a PDE edit code of 788. An updated PDE edit code spreadsheet will be posted on the CSSC website prior to the effective date of the change.
<b>Action - PACE</b>	Applicable to PACE. Refer to the memo for complete details on the closing of the 2015 PDE data.
<b>Action - MAPD</b>	Applicable to MAPD.
<b>CMS Memo Title &amp; Release Date</b>	Guidance for the Part D Payment Reconciliation Reopening for Calendar Year 2017 – Dated 04/29/2022
<b>Summary</b>	CMS will perform a program-wide reopening for the 2017 Part D Payment Reconciliation. The reopening will include CY 2017 PDE data submitted and accepted through 1:00 PM ET September 30, 2022. CMS will continue to accept CY 2017 PDE data after the September deadline; however, the data will not be considered in the reopening. For 2017 DIR changes, CMS will open the gates in HPMS for the resubmission of the 2017 DIR reports for Payment Reconciliation from July 1 through July 31, 2022.
<b>Action - PACE</b>	Applicable to PACE. Refer to the memo for complete details on the reopening and related deadlines.
<b>Action - MAPD</b>	Applicable to MAPD. Refer to the memo for complete details on the reopening and related deadlines.
<b>CMS Memo Title &amp; Release Date</b>	Continuation of the Prescription Drug Event (PDE) Reports and PDE Analysis Reporting Initiatives for the 2022 Benefit Year – Dated 04/29/2022
<b>Summary</b>	CMS announced the continuation of the PDE Reports and PDE Analysis initiatives for 2022 benefit year that support CMS’s efforts to improve the accuracy of PDE data. Information on the reports and the actions expected from participating sponsors is provided.

<b>Action - PACE</b>	Applicable to PACE. To add/change user authorization to access the PDE Analysis Reporting Web Portal, refer to the memo for additional details and instructions. Pharmastar can assist plans with the reports from the portal.
<b>Action - MAPD</b>	Applicable to MAPD. To add/change user authorization to access the PDE Analysis Reporting Web Portal, refer to the memo for additional details and instructions. Pharmastar can assist plans with the reports from the portal.
<b>CMS Email Title &amp; Release Date</b>	Issuance of Contract Year 2023 Model Materials – Dated 05/04/2022
<b>Summary</b>	CMS released the CY 2023 Model materials and highlighted the changes to the ANOC and EOC models and the Part D EOB. All models are available at the link provided.
<b>Action - PACE</b>	Informational to PACE.
<b>Action - MAPD</b>	Applicable to MAPD.
<b>CMS Memo Title &amp; Release Date</b>	Risk Adjustment Processing System (RAPS) and Encounter Data System (EDS) Submission – UPDATE – Dated 05/04/2022
<b>Summary</b>	CMS reminds organizations to report services provided via telehealth using modifier “95” for applicable encounter data records (EDRs) and chart review records (CRRs). Effective January 1, 2022, a new modifier “93” was added to the Current Procedural Terminology code set. Modifier 93 represents a “Synchronous telemedicine service rendered via telephone or other real-time interactive audio-only telecommunications system.” To report EDRs and CRRs for audio-only services (for dates of service on or after January 1, 2022) to the EDS, use modifier “93.”
<b>Action - PACE</b>	Applicable to PACE.
<b>Action - MAPD</b>	Applicable to MAPD.

**For the latest CMS response to COVID-19, please visit the [CMS.gov](https://www.cms.gov) website.**

Please note that this information is provided to you in summary form for general informational purposes only and does not constitute legal or regulatory compliance advice. It is your responsibility to consult with your Compliance Officer and/or legal counsel to determine applicability of any regulation or standards referenced herein to your organization and/or processes.